Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. van Meerten · SciRah

Researcher profile · Semantic Scholar

T. van Meerten

Share profile

T. van Meerten — researcher profile on SciRah

h-index: 30
Works: 163
Citations: 5,592

Most-cited papers

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
F. Locke, D. Miklos, C. Jacobson, M. Perales +27 more
2021New England Journal of Medicine1,192 citations Open access
Semantic Scholar
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
J. Westin, Olalekan O. Oluwole, M. Kersten, D. Miklos +26 more
2023New England Journal of Medicine334 citations Open access
Semantic Scholar
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
Olalekan O. Oluwole, K. Bouabdallah, J. Muñoz, S. de Guibert +23 more
2021British Journal of Haematology193 citations Open access
Semantic Scholar
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
M. Topp, T. van Meerten, R. Houot, M. Minnema +18 more
2021British Journal of Haematology131 citations Open access
Semantic Scholar
CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
R. Bouwstra, T. van Meerten, E. Bremer
2022Clinical and Translational Medicine107 citations Open access
Semantic Scholar
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of
M. Dreyling, J. Doorduijn, E. Giné, M. Jerkeman +34 more
2024The Lancet96 citations Open access
Semantic Scholar
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
G. Iacoboni, K. Rejeski, G. Villacampa, J. V. van Doesum +18 more
2021Blood Advances83 citations Open access
Semantic Scholar
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
S. Haggenburg, Q. Hofsink, Birgit I. Lissenberg-Witte, A. Broers +24 more
2022JAMA Oncology63 citations Open access
Semantic Scholar
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
S. Haggenburg, Birgit I. Lissenberg-Witte, R. V. van Binnendijk, G. den Hartog +44 more
2022Blood Advances56 citations Open access
Semantic Scholar
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Michael L. Wang, Wojciech Jurczak, M. Trněný, D. Belada +15 more
2025The Lancet Oncology47 citations Open access
Semantic Scholar
Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse.
C. Rusconi, Che-Ah Y. Chan, T. Eyre, D. Tucker +28 more
2022Blood40 citations Open access
Semantic Scholar
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study
D. Al-Sarayfi, M. Brink, M. Chamuleau, R. Brouwer +10 more
2023American journal of hematology/oncology38 citations Open access
Semantic Scholar
The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity
Yuan He, Martijn R Vlaming, T. van Meerten, E. Bremer
2022Cancers34 citations Open access
Semantic Scholar
Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
Michael L. Wang, W. Jurczak, M. Trněný, D. Belada +15 more
2023Blood33 citations
Semantic Scholar
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
J. Westin, F. Locke, M. Dickinson, A. Ghobadi +23 more
2023Clinical Cancer Research32 citations Open access
Semantic Scholar
CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
J. Freile, Natasha Ustyanovska Avtenyuk, M. Corrales, H. Lourens +4 more
2022Biomedicines31 citations Open access
Semantic Scholar
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
Olalekan O. Oluwole, E. Forcade, J. Munoz, S. de Guibert +22 more
2024Bone Marrow Transplantation30 citations Open access
Semantic Scholar
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
J. D. de Boer, K. Keijzer, E. Pennings, J. V. van Doesum +10 more
2023Cancers27 citations Open access
Semantic Scholar
CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties
Martijn R Vlaming, Vrouyr Bilemjian, J. Freile, H. Lourens +5 more
2021Scientific Reports27 citations Open access
Semantic Scholar
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
A. Spanjaart, E. Pennings, P. Mutsaers, S. van Dorp +17 more
2023Cancers26 citations Open access
Semantic Scholar
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity
Ewa Cendrowicz, L. Jacob, Shirley Greenwald, A. Tamir +19 more
2022Journal of experimental & clinical cancer research : CR26 citations Open access
Semantic Scholar
Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
F. Locke, D. Miklos, C. Jacobson, M. Perales +26 more
2021Blood26 citations Open access
Semantic Scholar
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
J. V. van Doesum, J. Salmanton-García, F. Marchesi, R. Di Blasi +46 more
2023Blood Advances25 citations Open access
Semantic Scholar
Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma
K. Keijzer, J. D. de Boer, J. V. van Doesum, W. Noordzij +4 more
2024Blood Cancer Journal17 citations Open access
Semantic Scholar
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
Q. Hofsink, S. Haggenburg, Birgit I. Lissenberg-Witte, A. Broers +25 more
2023EClinicalMedicine17 citations Open access
Semantic Scholar
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses
Yusheng Lin, Ghizlane Choukrani, L. Dubbel, Lena Rockstein +10 more
2024Experimental Hematology & Oncology16 citations Open access
Semantic Scholar
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
A. Spanjaart, E. Pennings, M. Kos, P. Mutsaers +12 more
2022JCO Oncology Practice16 citations Open access
Semantic Scholar
Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma
Myra Langendonk, M. D. de Jong, N. Smit, Jonas Seiler +7 more
2022Blood Cancer Journal15 citations Open access
Semantic Scholar
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients
A. Rutgers, P. Westerweel, B. van der Holt, S. Postma +25 more
2022PLoS ONE14 citations Open access
Semantic Scholar
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3
T. van Meerten, M. J. Kersten, G. Iacoboni, Georg Hess +22 more
2025Blood13 citations Open access
Semantic Scholar
Semi-automated 18F-FDG PET segmentation methods for tumor volume determination in Non-Hodgkin lymphoma patients: a literature review, implementation and multi-threshold evaluation
K. Keijzer, A. Niezink, J. D. de Boer, J. V. van Doesum +3 more
2023Computational and Structural Biotechnology Journal13 citations Open access
Semantic Scholar
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of Zuma-1 Cohort 6
Olalekan O. Oluwole, E. Forcade, J. Muñoz, S. de Guibert +22 more
2022Transplantation and Cellular Therapy13 citations Open access
Semantic Scholar
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
J. D. de Boer, E. Pennings, A. Kleinjan, J. V. van Doesum +13 more
2023Blood Advances11 citations Open access
Semantic Scholar
Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 Patients
A. Rutgers, P. Westerweel, B. van der Holt, S. Postma +25 more
2021Social Science Research Network11 citations
Semantic Scholar
Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.
Michael Wang, W. Jurczak, M. Trněný, D. Belada +16 more
2024Journal of Clinical Oncology10 citations Open access
Semantic Scholar
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
J. Westin, Olalekan O. Oluwole, M. J. Kersten, David B. Miklos +16 more
2023Hematological Oncology10 citations Open access
Semantic Scholar
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy
G. Iacoboni, K. Rejeski, Víctor Navarro, T. van Meerten +20 more
2025Leukemia8 citations Open access
Semantic Scholar
Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
T. van Meerten, M. J. Kersten, G. Iacoboni, Georg Hess +18 more
2024Blood8 citations
Semantic Scholar
Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
M. Tilch, C. Visco, S. Kinda, O. Hermine +13 more
2022HemaSphere8 citations Open access
Semantic Scholar
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
D. Al-Sarayfi, F. Meeuwes, M. Durmaz, D. Issa +12 more
2022Blood Cancer Journal7 citations Open access
Semantic Scholar
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
M. Dreyling, Jeanette Doorduijn, E. Giné, M. Jerkeman +34 more
2026The Lancet6 citations Open access
Semantic Scholar
Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.
Nora Liebers, A. Boumendil, H. Finel, Dominic Edelmann +23 more
2025Blood Cancer Discovery6 citations Open access
Semantic Scholar
High frequency of severe hyperglycemia observed during intensive hematological care: a prospective study using continuous glucose monitoring.
Marieke Tienstra, J. D. de Boer, J. V. van Doesum, K. Keijzer +9 more
2024Endocrine Practice6 citations Open access
Semantic Scholar
Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7
M. J. Kersten, Umar Farooq, A. Rapoport, F. Locke +21 more
2023Blood6 citations Open access
Semantic Scholar
Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
Myra Langendonk, N. Smit, W. Plattel, A. Diepstra +2 more
2022International Journal of Molecular Sciences6 citations Open access
Semantic Scholar
Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.
P. Borchmann, T. van Meerten, P. Bories, P. Dreger +23 more
2025Blood5 citations
Semantic Scholar
Prophylactic Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Olalekan O. Oluwole, K. Bouabdallah, J. Muñoz, S. de Guibert +22 more
20215 citations Open access
Semantic Scholar
Real-World Accuracy of Continuous Glucose Monitoring During Intensive Hematological Care: A Prospective Study
Marieke Tienstra, Riemer A. Been, J. D. de Boer, R. Gans +7 more
2025Diabetes Technology & Therapeutics4 citations Open access
Semantic Scholar
Patients With Relapsed Large B‐Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months
H. T. van der Galiën, H. Kooistra, R. Kibbelaar, N. Veeger +4 more
2025European Journal of Haematology4 citations Open access
Semantic Scholar
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study
J. D. de Boer, K. Keijzer, J. V. van Doesum, N. Smit +15 more
2025Nature Communications4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. V. van Doesum×14
Invite
J. V. van Doesum — researcher profile on SciRah
P. Mutsaers×13
Invite
P. Mutsaers — researcher profile on SciRah
M. Kersten×12
Invite
M. Kersten — researcher profile on SciRah
G. Huls×12
Invite
G. Huls — researcher profile on SciRah

×10

Invite

C. Jacobson — researcher profile on SciRah

Invite

M. Minnema — researcher profile on SciRah

Olalekan O. Oluwole×9

Invite

Olalekan O. Oluwole — researcher profile on SciRah

J. D. de Boer×9

Invite

J. D. de Boer — researcher profile on SciRah

C. Thieblemont×8

Invite

C. Thieblemont — researcher profile on SciRah

Invite

U. Farooq — researcher profile on SciRah

M. V. D. van der Poel×7

Invite

M. V. D. van der Poel — researcher profile on SciRah

Invite

F. Locke — researcher profile on SciRah